Most Favoured Nation Pricing: What 26 Company Agreements Actually Commit To

Sep 11, 2026 | News

Image Source: Generated by Google Gemini
Written by: LSDN Editorial Team
On behalf of: Life Science Daily News

Most favoured nation pricing is now the central instrument of United States drug pricing policy. On 31 August 2026, the White House announced agreements with nine further manufacturers. That brought the administration’s stated total to 26 companies, covering 89 per cent of the branded drug market. The official American term is most-favored-nation pricing, set out in an executive order signed in May 2025. Yet the headline count conceals a more important fact. What the 26 agreements oblige each company to do varies considerably between signatories.

What most favoured nation pricing is

The principle is simple. US prices for branded medicines are benchmarked against prices paid in other wealthy countries. The administration defines the most favoured nation price as the second lowest net price in a reference group. That group consists of the non-US G7 nations plus Denmark and Switzerland. The definition is set out in the White House Council of Economic Advisers report of May 2026.

Two distinct mechanisms sit underneath that principle, and coverage often conflates them.

The first covers existing medicines in state Medicaid programmes. Manufacturers offer supplemental rebates through the GENEROUS model. That model is a voluntary initiative announced by the Centers for Medicare and Medicaid Services in November 2025. The second mechanism covers future launches. Signatories commit to launching new medicines in the US at or near the most favoured nation price.

Neither mechanism sets commercial insurance prices. Neither replaces Medicare negotiation under the Inflation Reduction Act. Conflating Medicaid commitments with wider US pricing is a common source of confusion in coverage of these deals.

The legal basis matters too. The policy rests on executive action rather than statute. The White House has said it is working with Congress to codify the voluntary agreements into law. Alongside the August 2026 announcement it called on Congress to pass a wider package, the Great Healthcare Plan.

How the count reached 26

The timeline is worth stating precisely, because the count keeps moving.

President Trump signed Executive Order 14297 on 12 May 2025. On 31 July 2025 he wrote to 17 leading manufacturers, setting out the steps required of them. The first agreement, with Pfizer, followed on 30 September 2025. Four more came over the autumn, beginning with AstraZeneca in October. Nine further agreements were announced on 19 December 2025. They covered Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi. That took the White House running total to 14. TrumpRx.gov, the government direct-to-consumer platform, launched on 5 February 2026. By May 2026 the administration reported voluntary agreements with 17 of the largest manufacturers.

The 31 August 2026 announcement added nine mid-sized companies:

  • Alcon
  • Astellas Pharma
  • BeOne Medicines
  • BridgeBio
  • CSL
  • Kyowa Kirin
  • Sun Pharma
  • Teva Pharmaceuticals
  • UCB

That is the position as of 11 September 2026. The White House puts the total at 26 companies and 89 per cent of the branded market. President Trump described the figure as 90 per cent at the Oval Office announcement. He said the remainder of the industry would follow.

What the agreements commit companies to

The 31 August fact sheet sets out four broad commitments for the newest signatories.

State Medicaid programmes gain access to most favoured nation pricing on the nine companies’ products. The companies guarantee the same treatment for new medicines they bring to market. They collectively committed at least $19.6 billion to US manufacturing in the near term. Several also agreed to donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve.

Those donations are specific. UCB will contribute 163 tons of levetiracetam. Sun Pharma will contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline. Teva will contribute 45 metric tons of metronidazole and 4.8 tons of amlodipine. Astellas will contribute 25 kg of tacrolimus.

Tariff treatment is the other side of the exchange. Under the April 2026 Section 232 proclamation, covered pharmaceutical imports face a headline 100 per cent tariff. Companies with approved onshoring plans qualify for 20 per cent. Those that also sign pricing agreements with the Department of Health and Human Services pay nothing until January 2029. That linkage between pharmaceutical tariffs and pricing commitments is what gives the programme its leverage. The tariff proposals of late 2025 set out the UK exposure before the proclamation was signed.

Why most favoured nation pricing is not one thing

This is where the 26 agreements stop resembling a single instrument.

The American Action Forum, a centre-right policy institute, reviewed the publicised deals in September 2026. It found that manufacturers appear to have negotiated different combinations of commitments. Those combinations span pricing, manufacturing investment, tariff treatment, supply chain provisions and product-specific exceptions. Much of the detail sits in filings with the Securities and Exchange Commission rather than in the announcements. The Forum characterises the result as a series of bilateral negotiations rather than a transparent, generally applicable process.

Company filings bear that out. Gilead Sciences told investors its December 2025 agreement had four elements. It secured a three-year Section 232 exclusion, conditional on further US manufacturing investment. It agreed most favoured nation pricing in Medicaid for selected existing products and for future launches. It set a new direct-to-patient price for the hepatitis C treatment Epclusa. It also agreed to return part of any increased international revenues to the US government.

Scope varies enormously by portfolio. BeOne Medicines currently has only one product subject to Medicaid, the PD-1 inhibitor Tevimbra. BridgeBio’s commitment centres on Attruby, its sole commercial brand. GSK’s agreement extends to ViiV Healthcare and includes a 66 per cent discount on an Advair inhaler through TrumpRx. Genentech offers Xofluza at a 70 per cent discount on the same platform.

The executed agreements themselves have not been published. That absence is the practical obstacle to independent analysis. It is also what congressional letters have repeatedly sought to remedy.

Patient advocates make a related point about substance. Patients For Affordable Drugs said the newest deals concentrate on Medicaid, where steep discounts already exist. The group also noted that individual states can choose whether to participate.

The industry position runs the other way. PhRMA, the main US industry association, has argued that this is not the right route to lower costs. It points instead to pharmacy benefit managers as the cause of the price gap.

What most favoured nation pricing means outside the US

Because the reference basket is European, European prices now carry American consequences.

GlobalData analysis published in March 2026 found a 35 per cent fall in European product launches. The comparison covered the ten months after the policy was introduced. Countries in the GENEROUS reference basket saw a 37 per cent decline. The wider group of European countries referenced under the GLOBE and GUARD models fell 43 per cent. The analysts cautioned that regulatory delays and reimbursement negotiations could also explain part of the drop.

Two readings of the longer term are in play, and neither is settled.

The first holds that US prices will fall toward European levels. Global revenue would drop, and European systems would come under pressure to pay more. The UK case supports that reading. Under the December 2025 UK-US agreement, NICE raised its cost-effectiveness threshold by roughly 25 per cent from April 2026. The VPAG payment rate for newer medicines fell to 14.5 per cent in 2026, down from 22.9 per cent. It is capped at 15 per cent until 2028. UK pharmaceutical exports gained zero tariff treatment in return. Belgian deputy prime minister and health minister Frank Vandenbroucke put the criticism sharply in February 2026. The remark came in a Paris address reported by Applied Policy. He argued that the Trump administration wants “European prices without the European model”.

The second reading is more cautious. List prices may rise while confidential net prices absorb the difference. Manufacturers may simply delay or skip launches in lower-priced markets. That pattern would leave headline convergence without much real transfer. It would also worsen access in the very countries used as benchmarks. Either way, most favoured nation pricing compounds the UK competitiveness pressures that were already building through 2025.

What to watch

Three things will determine how much this matters by 2027.

Congressional scrutiny is the first. Lawmakers wrote to the administration and to manufacturers in early 2026. They requested executed agreements, enforcement detail and spending analyses. Sidley Austin has noted reports of forthcoming legislation from Senator Ron Wyden. That bill would require disclosure of the agreements. Any attempt to codify the framework in statute would face the same questions.

Coverage of the remaining market is the second. Roughly 11 per cent of the branded market has not signed. Mid-sized companies with one or two products have less portfolio diversity to absorb revenue pressure.

Company disclosure is the third. Quantified revenue effects in quarterly filings will test the administration’s savings claims. The Council of Economic Advisers estimates $600 billion of savings over the next decade. That figure is an administration estimate. Independent verification remains difficult while the agreement texts stay confidential. Analysts tracking the knock-on effects on falling drug prices and on Medicare coverage decisions will be reading those filings closely.

Most favoured nation pricing has broadened quickly. Whether it has deepened is a different question, and the agreements do not yet answer it.

    References:
    1. The White House, 2026. Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans. https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-with-nine-additional-pharmaceutical-manufacturers-to-lower-drug-prices-for-americans/
    2. American Action Forum, 2026. Most-Favored-Nation Drug Pricing Gets Broader, Not Better. https://www.americanactionforum.org/weekly-checkup/most-favored-nation-drug-pricing-gets-broader-not-better/
    3. Sidley Austin, 2026. Most-Favored-Nation Drug Pricing Policy: Executive Actions, Manufacturer Agreements, and Growing Congressional Scrutiny. https://www.sidley.com/en/insights/newsupdates/2026/04/most-favored-nation-drug-pricing-policy-executive-actions-manufacturer-agreements
    4. Gilead Sciences, 2026. Form 10-Q for the quarterly period ended 30 June 2026. https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000031/gild-20260630.htm
    5. Pharmaceutical Technology, 2026. The Most Favored Nation Policy: early insights into Europe’s response. https://www.pharmaceutical-technology.com/analyst-comment/most-favored-nation-policy-early-insights-into-europe-response/
    6. The White House Council of Economic Advisers, 2026. Savings from Most-Favored-Nation Drug Pricing Policy. https://www.whitehouse.gov/research/2026/05/savings-from-most-favored-nation-drug-pricing-policy/
    7. CNBC, 2026. Trump strikes new drug pricing deals with nine midsized drugmakers. https://www.cnbc.com/2026/08/31/trump-drug-pricing-deals.html
    8. Applied Policy, 2026. MFN Policies Reshape Markets and Market Access Strategies. https://www.appliedpolicy.com/mfn-policies-reshape-markets-and-market-access-strategies/
    All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions.

    Articles that may be of interest

    Weekly News Roundup | 16 November 2026

    Weekly News Roundup | 16 November 2026

    Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...

    read more
    Weekly News Roundup | 9 November 2026

    Weekly News Roundup | 9 November 2026

    Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

    read more
    Weekly News Roundup | 2 November 2026

    Weekly News Roundup | 2 November 2026

    Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

    read more

    Articles that may be of interest

    Weekly News Roundup | 16 November 2026

    Weekly News Roundup | 16 November 2026

    Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...

    read more
    Weekly News Roundup | 9 November 2026

    Weekly News Roundup | 9 November 2026

    Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

    read more
    Weekly News Roundup | 2 November 2026

    Weekly News Roundup | 2 November 2026

    Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

    read more